NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 3 filers reported holding NABRIVA THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $1,410,000 | -55.0% | 2,644,600 | -43.1% | 0.02% | -59.1% |
Q2 2020 | $3,133,000 | +17.3% | 4,644,600 | 0.0% | 0.04% | -2.2% |
Q1 2020 | $2,671,000 | -56.4% | 4,644,600 | 0.0% | 0.04% | -48.9% |
Q4 2019 | $6,131,000 | -34.0% | 4,644,600 | 0.0% | 0.09% | -50.0% |
Q3 2019 | $9,289,000 | -17.7% | 4,644,600 | 0.0% | 0.18% | +0.6% |
Q2 2019 | $11,286,000 | -0.4% | 4,644,600 | 0.0% | 0.18% | 0.0% |
Q1 2019 | $11,333,000 | +67.1% | 4,644,600 | 0.0% | 0.18% | +40.0% |
Q4 2018 | $6,781,000 | -45.9% | 4,644,600 | 0.0% | 0.12% | -17.2% |
Q3 2018 | $12,540,000 | -8.1% | 4,644,600 | +18.5% | 0.15% | -7.4% |
Q2 2018 | $13,640,000 | -30.8% | 3,919,600 | 0.0% | 0.16% | -33.2% |
Q1 2018 | $19,716,000 | -15.9% | 3,919,600 | 0.0% | 0.24% | -17.6% |
Q4 2017 | $23,439,000 | -27.0% | 3,919,600 | 0.0% | 0.30% | -3.6% |
Q3 2017 | $32,102,000 | -21.8% | 3,919,600 | 0.0% | 0.31% | -28.8% |
Q2 2017 | $41,077,000 | – | 3,919,600 | – | 0.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
FIRST NATIONAL CORP /MA/ /ADV | 1,000 | $941,000 | 0.61% |
Aisling Capital Management LP | 1,910,287 | $1,098,000 | 0.48% |
Values First Advisors, Inc. | 410,653 | $236,125 | 0.28% |
FRAZIER MANAGEMENT LLC | 4,256,526 | $2,448,000 | 0.28% |
Vivo Capital, LLC | 1,704,130 | $980,000 | 0.09% |
SABBY MANAGEMENT, LLC | 367,613 | $211,000 | 0.09% |
Orbimed Advisors | 4,644,600 | $2,671,000 | 0.04% |
Rock Springs Capital Management LP | 1,050,000 | $604,000 | 0.02% |
Clear Creek Financial Management, LLC | 112,000 | $62,000 | 0.02% |
EXANE DERIVATIVES | 82,078 | $47,193,000 | 0.01% |